Novo Nordisk News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.09.24	EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' (Benzinga)
24.09.24	Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO (Benzinga)
24.09.24	Novo Nordisk CEO spars with lawmakers over Ozempic, Wegovy prices (MarketWatch)
24.09.24	'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing (Benzinga)
23.09.24	Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday (Benzinga)
23.09.24	Novo Nordisk faces US Senate grilling over price of weight loss drugs (Financial Times)
22.09.24	Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? (Benzinga)
21.09.24	Novo Nordisk Aktie ist Lieblingsaktie der Deutschen neben US Big Tech wie Apple und Amazon (manager magazin online)
21.09.24	Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today (MotleyFool)
20.09.24	Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients (Benzinga)
20.09.24	EU gibt grünes Licht: Wegovy-Label-Erweiterung - Novo Nordisk-Aktie im Minus (Dow Jones) Novo Nordisk kann auf eine Erweiterung der EU-Zulassung seines Abnehm-Medikaments Wegovy setzen.» mehr
19.09.24	Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity (Benzinga)
19.09.24	Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks (MotleyFool)
18.09.24	Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications (Benzinga)
18.09.24	MÄRKTE EUROPA/Knapp behauptet vor Fed-Entscheidung - Campari sehr schwach (Dow Jones)
18.09.24	This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments (MotleyFool)
18.09.24	MÄRKTE EUROPA/Knapp behauptet - BASF mit IPO-Fantasie gesucht (Dow Jones)
12.09.24	Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now (MotleyFool)
11.09.24	MÄRKTE EUROPA/Etwas fester - US-Daten sprechen für kleinen Zinsschritt (Dow Jones)
11.09.24	MÄRKTE EUROPA/Börsen reagieren volatil auf US-Preisdaten - Euro fällt (Dow Jones)
11.09.24	Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy (Benzinga)
11.09.24	Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval (Benzinga)
11.09.24	Novo Nordisk claims obesity drug effective for under-12s (Financial Times)
11.09.24	Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds. (MarketWatch)
09.09.24	Evaluating Novo Nordisk: Insights From 8 Financial Analysts (Benzinga)
06.09.24	What the Options Market Tells Us About Novo Nordisk (Benzinga)
05.09.24	Novo Nordisk Unusual Options Activity (Benzinga)
05.09.24	Eli Lilly’s weekly insulin intensifies race with Novo Nordisk (MarketWatch)
31.08.24	These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now (MotleyFool)
30.08.24	Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients (Benzinga)
27.08.24	Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble? (MotleyFool)
26.08.24	Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices (Benzinga)
25.08.24	This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money (MotleyFool)
23.08.24	These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk (MotleyFool)
23.08.24	Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead (MotleyFool)
22.08.24	What the Options Market Tells Us About Novo Nordisk (Benzinga)
21.08.24	Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle (Benzinga)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’122.50	1.04 %	K V
UBS Group	30.93	1.01 %	K V
Geberit	629.00	1.00 %	K V
ABB	53.30	0.57 %	K V
Logitech Intl	75.20	-0.61 %	K V
Lonza Grp	576.20	-0.69 %	K V
Givaudan	3’472.00	-0.77 %	K V
Swiss Re	146.15	-0.88 %	K V
Sonova Hldg	226.20	-2.75 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novo Nordisk Aktie VALOR 461641 / ISIN US6701002056

Nachrichten zu Novo Nordisk (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten